Literature DB >> 11848502

Variations of EGF-R surface expression in squamous cell carcinomas of the head and neck region.

R Mandic1, N Eikelkamp, R Peldszus, M Sadowski, A M Sesterhenn, A A Dünne, J A Werner.   

Abstract

BACKGROUND: It has been previously found that the epidermal growth factor receptor (EGF-R) is highly expressed in squamous cell carcinomas of the head and neck region (SCCHN) and that this expression correlates with malignant transformation and tumor development.
MATERIALS AND METHODS: We examined 9 SCCHN cell lines and a control keratinocyte cell line for EGF-R expression, utilizing fluorescence-activated cell sorting (FACS) and Western blot analysis. Immuno-cytochemistry was performed to evaluate the receptor's cellular distribution.
RESULTS: We found the EGF-R to be up-regulated in SCCHN. Surprisingly we did not see a clear correlation between tumor staging, grading or Stat3 signaling and EGF-R level but we observed up to three distinct EGF-R specific bands in our Western blots, implicating the presence of different protein isoforms.
CONCLUSION: Our data suggest that not only the amount but also the receptor function, including the presence of mutations, need to be considered in SCCHN malignancies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11848502

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF.

Authors:  Heewa Kareem; Karl Sandström; Ronny Elia; Lars Gedda; Matti Anniko; Hans Lundqvist; Marika Nestor
Journal:  Tumour Biol       Date:  2010-01-30

2.  Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates.

Authors:  Gargi Ghosh; Andrew G Lee; Sean P Palecek
Journal:  Anal Biochem       Date:  2009-07-05       Impact factor: 3.365

3.  A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.

Authors:  El Mustapha Bahassi; Ya-Qin Li; Trisha M Wise-Draper; Li Deng; Jiang Wang; Colleen N Darnell; Keith M Wilson; Susanne I Wells; Peter J Stambrook; Olivier Rixe
Journal:  Eur J Cancer       Date:  2013-04-08       Impact factor: 9.162

4.  Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891.

Authors:  Natsumi Uehara; Naoki Otsuki; Mie Kubo; Junko Kitamoto; Yasutaka Kojima; Masanori Teshima; Hirotaka Shinomiya; Toshiro Shirakawa; Ken-Ichi Nibu
Journal:  Cancer Rep (Hoboken)       Date:  2020-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.